vs

Side-by-side financial comparison of Iridium Communications Inc. (IRDM) and TransMedics Group, Inc. (TMDX). Click either name above to swap in a different company.

Iridium Communications Inc. is the larger business by last-quarter revenue ($219.1M vs $160.8M, roughly 1.4× TransMedics Group, Inc.). TransMedics Group, Inc. runs the higher net margin — 65.6% vs 9.9%, a 55.7% gap on every dollar of revenue. On growth, TransMedics Group, Inc. posted the faster year-over-year revenue change (32.2% vs 1.9%). Over the past eight quarters, TransMedics Group, Inc.'s revenue compounded faster (28.8% CAGR vs 4.4%).

Iridium Communications Inc. is a publicly traded American company headquartered in McLean, Virginia, United States. Iridium operates the Iridium satellite constellation, a system of 80 satellites: 66 are active satellites and the remaining fourteen function as in-orbit spares. Iridium Satellites are used for worldwide voice and data communication from handheld satellite phones, satellite messenger communication devices and integrated transceivers, as well as for two-way satellite messaging se...

TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.

IRDM vs TMDX — Head-to-Head

Bigger by revenue
IRDM
IRDM
1.4× larger
IRDM
$219.1M
$160.8M
TMDX
Growing faster (revenue YoY)
TMDX
TMDX
+30.2% gap
TMDX
32.2%
1.9%
IRDM
Higher net margin
TMDX
TMDX
55.7% more per $
TMDX
65.6%
9.9%
IRDM
Faster 2-yr revenue CAGR
TMDX
TMDX
Annualised
TMDX
28.8%
4.4%
IRDM

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IRDM
IRDM
TMDX
TMDX
Revenue
$219.1M
$160.8M
Net Profit
$21.6M
$105.4M
Gross Margin
58.1%
Operating Margin
23.2%
13.2%
Net Margin
9.9%
65.6%
Revenue YoY
1.9%
32.2%
Net Profit YoY
1436.9%
EPS (diluted)
$2.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRDM
IRDM
TMDX
TMDX
Q1 26
$219.1M
Q4 25
$212.9M
$160.8M
Q3 25
$226.9M
$143.8M
Q2 25
$216.9M
$157.4M
Q1 25
$214.9M
$143.5M
Q4 24
$213.0M
$121.6M
Q3 24
$212.8M
$108.8M
Q2 24
$201.1M
$114.3M
Net Profit
IRDM
IRDM
TMDX
TMDX
Q1 26
$21.6M
Q4 25
$24.9M
$105.4M
Q3 25
$37.1M
$24.3M
Q2 25
$22.0M
$34.9M
Q1 25
$30.4M
$25.7M
Q4 24
$36.3M
$6.9M
Q3 24
$24.4M
$4.2M
Q2 24
$32.3M
$12.2M
Gross Margin
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
58.1%
Q3 25
58.8%
Q2 25
61.4%
Q1 25
61.5%
Q4 24
59.2%
Q3 24
55.9%
Q2 24
60.6%
Operating Margin
IRDM
IRDM
TMDX
TMDX
Q1 26
23.2%
Q4 25
25.9%
13.2%
Q3 25
30.9%
16.2%
Q2 25
23.2%
23.2%
Q1 25
28.1%
19.1%
Q4 24
24.5%
7.1%
Q3 24
25.8%
3.6%
Q2 24
21.7%
10.9%
Net Margin
IRDM
IRDM
TMDX
TMDX
Q1 26
9.9%
Q4 25
11.7%
65.6%
Q3 25
16.4%
16.9%
Q2 25
10.1%
22.2%
Q1 25
14.2%
17.9%
Q4 24
17.1%
5.6%
Q3 24
11.5%
3.9%
Q2 24
16.1%
10.7%
EPS (diluted)
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
$0.24
$2.59
Q3 25
$0.35
$0.66
Q2 25
$0.20
$0.92
Q1 25
$0.27
$0.70
Q4 24
$0.30
$0.19
Q3 24
$0.21
$0.12
Q2 24
$0.27
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRDM
IRDM
TMDX
TMDX
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
Stockholders' EquityBook value
$473.1M
Total Assets
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
$96.5M
Q3 25
$88.5M
Q2 25
$79.3M
Q1 25
$50.9M
Q4 24
$93.5M
Q3 24
$159.6M
$330.1M
Q2 24
$63.5M
$362.8M
Total Debt
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
$1.8B
Q3 25
Q2 25
Q1 25
Q4 24
$1.8B
Q3 24
Q2 24
Stockholders' Equity
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
$462.6M
$473.1M
Q3 25
$450.5M
$355.2M
Q2 25
$473.6M
$318.1M
Q1 25
$518.4M
$266.3M
Q4 24
$576.6M
$228.6M
Q3 24
$663.8M
$209.9M
Q2 24
$786.7M
$189.9M
Total Assets
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
$2.5B
$1.1B
Q3 25
$2.6B
$946.0M
Q2 25
$2.6B
$890.5M
Q1 25
$2.6B
$837.5M
Q4 24
$2.7B
$804.1M
Q3 24
$2.8B
$785.6M
Q2 24
$2.7B
$758.6M
Debt / Equity
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
3.80×
Q3 25
Q2 25
Q1 25
Q4 24
3.05×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRDM
IRDM
TMDX
TMDX
Operating Cash FlowLast quarter
$34.5M
Free Cash FlowOCF − Capex
$19.0M
FCF MarginFCF / Revenue
11.8%
Capex IntensityCapex / Revenue
13.7%
9.7%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$133.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
$108.6M
$34.5M
Q3 25
$100.8M
$69.6M
Q2 25
$129.6M
$91.6M
Q1 25
$61.1M
$-2.9M
Q4 24
$104.8M
$19.7M
Q3 24
$118.6M
$6.9M
Q2 24
$81.1M
$25.7M
Free Cash Flow
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
$75.1M
$19.0M
Q3 25
$79.2M
$61.9M
Q2 25
$108.9M
$82.5M
Q1 25
$36.5M
$-29.9M
Q4 24
$80.5M
$6.1M
Q3 24
$100.0M
$-41.3M
Q2 24
$68.7M
$2.0M
FCF Margin
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
35.3%
11.8%
Q3 25
34.9%
43.1%
Q2 25
50.2%
52.4%
Q1 25
17.0%
-20.8%
Q4 24
37.8%
5.0%
Q3 24
47.0%
-38.0%
Q2 24
34.2%
1.7%
Capex Intensity
IRDM
IRDM
TMDX
TMDX
Q1 26
13.7%
Q4 25
15.7%
9.7%
Q3 25
9.5%
5.3%
Q2 25
9.5%
5.8%
Q1 25
11.4%
18.8%
Q4 24
11.4%
11.2%
Q3 24
8.7%
44.3%
Q2 24
6.2%
20.8%
Cash Conversion
IRDM
IRDM
TMDX
TMDX
Q1 26
Q4 25
4.37×
0.33×
Q3 25
2.71×
2.86×
Q2 25
5.90×
2.62×
Q1 25
2.01×
-0.11×
Q4 24
2.88×
2.87×
Q3 24
4.85×
1.63×
Q2 24
2.51×
2.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRDM
IRDM

Voice and data$57.4M26%
IoT data (2)$46.0M21%
Government$39.5M18%
Government service revenue (5)$27.6M13%
Subscriber equipment$20.2M9%
Hosted payload and other data service (4)$14.8M7%
Broadband (3)$12.2M6%
Commercial$1.3M1%

TMDX
TMDX

Liver Product$127.0M79%
Heart Product$26.0M16%
Other$5.9M4%
Lung Product$1.9M1%

Related Comparisons